Recent Updates
Recently added Catalysts
CVRX Negative Sentiment Score: 25/100

CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Key Takeaway: CVRx, Inc. is currently under investigation by Bronstein, Gewirtz & Grossman, LLC for potential investor claims following a significant drop in its share price. This decline was triggered by proposed reimbursement cuts from the Centers for Medicare and Medicaid Services (CMS) affecting the company's heart failure device. Specifically, CMS indicated a reduction of 38.1% for Ambulatory Surgical Center services and 32.9% for hospital outpatient services. Investors are being encouraged to report any relevant information regarding the investigation.

Market Sentiment Analysis

CONCERNS & RISKS

  • Significant decline in CVRx's stock price by over 38.5%.
  • Proposed payment rate cuts for their heart failure device by CMS.
  • Potential legal implications from the investigation by law firm Bronstein, Gewirtz & Grossman.

Full Press Release Details

NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. (“CVRx” or “the Company”) (NASDAQ: CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/CVRX.
Investigation Details
On July 10, 2024, the Centers for Medicare and Medicaid Services (“CMS”) issued proposed payment rates for outpatient and Ambulatory Surgical Center (“ASC”) services. Piper Sandler issued a note indicating that under the CMS rules, reimbursement for CVRx’s heart failure device would fall by 38.1% for ASC services and by 32.9% for hospital outpatient services. Based on this news, shares of CVRx dropped over 38.5% on the same day.
If you are aware of any facts relating to this investigation or purchased CVRx securities, you can assist this investigation by visiting the firm’s site: bgandg.com/CVRX. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the investigation involving CVRx, Inc.?

The investigation pertains to potential claims for investors of CVRx, Inc. following significant share price drops.

How much did CVRx's shares drop after CMS proposed payment rates?

Shares of CVRx fell over 38.5% on July 10, 2024, after CMS's proposed payment rate announcement.

Who can assist with the CVRx investigation?

Investors who purchased CVRx securities can assist the investigation by visiting bgandg.com/CVRX.

Is there any cost to participate in this investigation?

There is no cost for investors; the firm operates on a contingency fee basis.

What is Bronstein, Gewirtz & Grossman, LLC known for?

The firm is recognized for representing investors in securities fraud class actions successfully.

Last updated: Aug 13, 2024